NCT04838834View on ClinicalTrials.gov

Monitoring Serologic Response to Severe Acute Respiratory Syndrome-2 (SARS-COV-2)/COVID-19 in Children

CompletedOBSERVATIONAL
Enrollment

472

Participants

Timeline

Start Date

May 15, 2020

Primary Completion Date

February 10, 2025

Study Completion Date

February 10, 2025

Conditions
COVID-19SARS-CoV-2Inflammatory Bowel Diseases
Trial Locations (1)

06106

Connecticut Children's Medical Center, Hartford

All Listed Sponsors
collaborator

The Jackson Laboratory

OTHER

collaborator

Food and Drug Administration (FDA)

FED

lead

Connecticut Children's Medical Center

OTHER

NCT04838834 - Monitoring Serologic Response to Severe Acute Respiratory Syndrome-2 (SARS-COV-2)/COVID-19 in Children | Biotech Hunter | Biotech Hunter